Mets give away Johan Santana's plan

6 Comments

Mets pitching coach Dan Warthen told the New York Daily News on Monday that Johan Santana is racking up high pitch counts early in games because of a plan that calls for him throw mostly inside fastballs the first time through the lineup.
The plan is designed to make his changeup more effective as the game goes on, and it’s probably a decent strategy, as long as he mixes it up from time to time.
But why is Warthen telling the whole world that such a plan exists? Is he or the organization so insecure that there’s a need to justify one bad outing from the game’s highest-paid pitcher?
Sure, any team with an advance scout worth his paycheck has already figured it out, but that doesn’t mean you give it away. Now every hitter in the league knows for sure. Now every scout watching the Mets is going to looking extra hard at similar patterns for the rest of the team’s starters.
Before you know it, the rest of the league will catch on to the fact that if you’re facing Oliver Perez and you stand in the box with the bat on your shoulder, you’re more likely than not to walk.
I’m as bored by generic answers from players and coaches as anyone, but Warthen should take a lesson. Unless he’s actually designing some new masterplan for Santana to be unveiled in the left-hander’s next start and this is just some grand misdirection, then he’s done the Mets a disservice.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
0 Comments

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.